CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Catalent celebrates ground breaking for expanded biologics facility
News
24 Oct 2016

Catalent celebrates ground breaking for expanded biologics facility

Company to invest $34 million in facility extension to add a new 2 x 2,000 L single-use bioreactor system and laboratory space.

Catalent Pharma Solutions celebrated its ground breaking for a new $34 million extension to its state-of-the-art Madison, Wisconsin biologics manufacturing facility on Friday 21 October 21. When completed, the additional 22,000 sq ft of space will accommodate a new 2 x 2,000 L single-use bioreactor system, allowing the company to support late-phase clinical and commercial production of up to 4,000 L batches. The new footprint will also support expansion of analytical and process development laboratories, as well as additional office space.

The ground breaking ceremony, led by Lieutenant Governor of Wisconsin Rebecca Kleefisch and Catalent President and CEO John Chiminski, marks the beginning of construction at the site that will eventually create more than 100 new jobs.

“I want to thank the company for its continued commitment to Wisconsin by deciding to grow here,” said Lt. Governor Kleefisch. “This expansion will further enhance the Madison region’s leadership position in the pharmaceutical and health industries.”

The Wisconsin Economic Development Corporation (WEDC) has awarded Catalent with up to $1 million in state tax credits over the next 3 years. The actual amount of credits the company will receive is contingent upon the level of capital investment in Madison during the 3-year period.

“Our continued investment in biologics capabilities is in direct response to market demand, where underlying growth for large molecules is expected to exceed that for small molecule drugs,” commented Barry Littlejohns, Catalent’s President of Drug Delivery Solutions. “We are immensely proud of our facility, and the people here in Madison who have helped achieve our customers’ program milestones and move toward larger commercial programs,” he added.